Clinical Trials
99 trialsDose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
A Study of PHN-010 in Patients With Advanced Solid Tumors
Pheon Therapeutics
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Seagen Inc.
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
National Institutes of Health Clinical Center (CC)
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Fusion Pharmaceuticals Inc.
(VELA) Study of BLU-222 in Advanced Solid Tumors
Blueprint Medicines Corporation
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Incyte Corporation
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Sutro Biopharma, Inc.
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Pfizer
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
Novartis
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
AM-003
University of Virginia
A Study to Investigate LYL797 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Dana-Farber Cancer Institute
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Pfizer
C4431001
Pfizer
MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Pennsylvania
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Seagen Inc.
A Study of SGN-ALPV in Advanced Solid Tumors
Seagen Inc.
A Study of SGN-STNV in Advanced Solid Tumors
Seagen Inc.
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Novartis
Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Pfizer
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
Hoffmann-La Roche
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
ABM Therapeutics Corporation
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Kyowa Kirin Co., Ltd.
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Pfizer
A Study of PY314 in Subjects With Advanced Solid Tumors
Ikena Oncology
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Haihe Biopharma Co., Ltd.
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b
Mersana Therapeutics
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Stingthera, Inc.
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Gilead Sciences
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Atreca, Inc.
ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
Bayer
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
SCRI Development Innovations, LLC
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Leap Therapeutics, Inc.
BRCA
University of Alabama at Birmingham
BrUOG 390: Neoadjuvant Treatment With Talazoparib
Brown University
Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer
Ludwig Institute for Cancer Research
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics